Clinical Trial Update: Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating donor-derived natural killer cell infusions for refractory non-B lineage hematologic cancers and solid tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Myelodysplastic Syndrome
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Donor-derived natural killer cell infusion (donor-derived natural killer cells)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell | Phase 1 | Status: COMPLETED